GlassScriptPhysician profile
Jay Dennis Tarnow
NPI 1619089885
$5,954.05
in general payments reported to CMS, 2019-2025
25 companies · $541 in 2025
The $541 reported for 2025 was more than what 77% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $752 · 2021: $790 · 2022: $1,076 · 2023: $947 · 2024: $609 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $952.13 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $796.33 | 2019-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $732.80 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $727.17 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $539.41 | 2021-2025 | Vraylar |
| Lundbeck LLC | $352.17 | 2020-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $284.70 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $240.56 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.41 | 2021-2023 | |
| Tris Pharma INC | $197.90 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $142.69 | 2019-2023 | Austedo Xr |
| Neos Therapeutics, LP | $129.81 | 2020-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Shire North American Group INC | $128.22 | 2019 | |
| Noven Therapeutics, LLC | $122.77 | 2023-2024 | Xelstrym |
| Janssen Pharmaceuticals, INC | $69.57 | 2019-2024 | Spravato |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $66.10 | 2019-2023 | Subvenite, Lamotrigine |
| Adlon Therapeutics L.P. | $57.04 | 2019 | |
| Neurocrine Biosciences, INC. | $39.24 | 2019-2021 | |
| Bausch Health US, LLC | $34.93 | 2022-2024 | Aplenzin, Wellbutrin |
| Vertical Pharmaceuticals, LLC | $31.05 | 2019-2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $23.90 | 2021 | |
| Aytu Biopharma, INC. | $20.14 | 2021 | |
| Axsome Therapeutics, INC. | $18.42 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2025 | Cobenfy |
| Eisai INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Tarnow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.